Allogene R&D EVP’s Tax‑Cover Sale Sparks Mixed Investor Buzz, Not a Confidence Drop #AllogeneTherapeutics #InsiderMoves #MarketSentiment
Allogene Therapeutics insider sell‑to‑cover by R&D EVP is a routine tax move, not a sign of declining confidence; investors see neutral impact and upside potential.
3 minutes to read